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Summan- We studied the effect of early postoperative chemotherapy. including 5-fluorouracil (5-FU) for 5
davs for patients With gastric cancer following noncurative resection. The study was prospectively randomised
and controlled. and 162 (87.1 zo) of 186 were eligible candidates for statistical assessment. Patients randomised
to group A received therapy that is used widely to treat patients With gastric cancer in Japan: mitomycin C
(MMC). OK-432. UFT and PSK. Patients randomised to group B received the same drugs given to group A
plus 5-FU bolus injections for 5 days. beginning on postoperative dav 2. There were no differences in
prognostic factors and doses of the drugs prescribed. except for 5-EU. There was no difference in the toxicitV
rate between the groups. Generalised Wilcoxon test revealed a P *-alue of 0.169. and the 500o survival rate
improved 1.4-fold in patients with gastric cancer treated With earlv postoperative chemotherapy of MMC.
OK-432 plus 5-FU injection.
The early detection of gastric cancer by upper G.I. series.
endoscopy. extensive lymph node dissection (Kodama et al..
1981: Boku et al.. 1989) and postoperative adjuvant
chemotherapy (Kano et al.. 1981: Gastrointestinal Tumor
Study Group. 1982; Inokuchi et al.. 1984) have led to a
longer survival time for approximately 60% of curatively
resected patients. Patients With a far advanced cancer are
usually treated by palliative resection. As tumour foci remain
in these patients. antitumour drugs are required to suppress
tumour growth. Kano et al. (1982) reported that post-
operative long-term cancer chemotherapy (PLCC) with a
combination of mitomycin C (MMC). 1-(2-tetrahydrofurvl)-
5-fluorouracil (tegafur) and PSK led to a life-prolongation
for patients With noncuratively resected stage IV gastric
cancer. however. the clinical effects are not satisfactory. The
doubling time of tumour cells in a small population focus is
often shorter than in a larger population focus (Schabel.
1975: Gunduz et al.. 1979). hence. tumour foci remaining
after a noncurative resection are expected to be more sensi-
tive to cell-cycle specific drugs. For these reasons. intensive
remission-induction followed bv maintenance therapy should
be given due consideration. 5-Fluorouracil (5-FU) admini-
stration has been prescribed for 5 days for the patients with
advanced gastric cancer. in combination with MMC and
other drugs (Haller. 1988). In 162 patients. we examined the
effect of adding 5-FU bolus injections for 5 days during
induction therapy With MMC and OK432 (Maehara et al..
1990a).
Materials and methods
Patients
All patients included in the prospectively randomised and
controlled trial underwent a macroscopic noncurative gastric
resection. The 186 patients were entered into this studv
between July 1986 and June 1988. The patients were
assigned. at random. to either group A or B on the day of
operation. The protocol (Figure 1) was as follows. The
inductive regimen for group A included mitomycin C (MMC)
(Inokuchi et al.. 1984) 20 mg intravenous (iL.) injection on
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Figure I Schedule for administration of chemotherapy.
the day of operation. 10 mg on postoperative day 1. and
10 mg even, month thereafter for 1 year. and OK432
(Uchida & Hoshino. 1980). 20 KE intraperitoneal (i.p.) injec-
tion on the day of the operation and 5 KE intradermal (i.d.)
injections on postoperative days 3. 5. 7. 9. 11. 1 KE of
OK-432 is equivalent to a 0.1 mg lyophilised preparation of
heat-killed Streptococcus hemoltvticus. For maintenance
therapy. group A received UFT (Ota et al.. 1988: Maehara et
al.. 1989: Maehara et al.. 1990b). a combination of tegafur
and uracil in a molar ratio of 1:4. 400 mg orally daily. and
PSK (Tsukagoshi et al.. 1984). 3 g orallv daily beginning
2 weeks after the operation. for 1 year. PSK is a protein-
bound preparation. extracted from Coriolus versicolor which
belongs to Basidiomv cetes. The regimen for group B included
regimen A plus 5-FU 250 mg i.v. bolus injections on post-
operativ-e days 2-6. Patients were selected on the basis of: (1)
histological diagnosis of gastric cancer: (2) macroscopic diag-
nosis as a noncurative case. on completion of surgical proce-
dures: (3) age less than 76 years: (4) performance status grade
of 0-3: (5) no evident synchronous or metachronous double
cancer: (6) adequate organ system function (leukocytes
>4.000 mm-. platelets >100.000 mm-. GOT and GPT
<100 U). Pathological diagnosis and classifications were
evaluated according to the General Rules for the Gastnrc
Cancer Study in Surgery and Pathology in Japan (Japanese
Research Societ) for Gastnrc Cancer. 1981).
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Table I Comparison of clinicopathological characteristics between patients in
groups A and B
Factor
Sex
Age
Location of tumour
Tumour maximal
diameter (cm)
Macroscopic
appearance
Macroscopic stage
Histological stage
Macroscopic
curability
Histological
curability
Macroscopic cancer-
infiltration at the
resection margin
Histological cancer-
infiltration at the
resection margin
Serosal invasion
Histological depth
of invasion
Categorn
Male
Female
Upper (C)
Middle (M)
Lower (A)
type 1
type 2
type 3
type 4
type 5
Unknownb
III
IV
II
III
IV
Unknownb
RNC
ANC
RC
RNC
ANC
Unknownb
(-)
(+)
Unknownb
(-)
(+)
Unknownb
So
Si
S2
S3
Unknownb
No serosal
invasion
With serosal
invasion
Invasion into
neighbouring
structures
Group A
(n = 82)
53
29
60.2 ± 11.3*
18
31
33
8.4± 3.8a
0
19
33
22
4
4
4
78
0
7
74
1
13
69
4
7
69
2
69
7
6
60
18
4
2
2
45
33
0
8
54
12
Group B
(n =80)
55
25
59.1 + 11.6
19
32
29
8.6± 3.5
15
35
21
4
3
5
75
3
5
69
3
18
62
3
13
60
4
69
8
3
52
20
8
2
2
33
42
1
16
P value
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
39
17
Unknown' 8 8
Macroscopic lymph NO 0 3 NS
node metastasis NI 9 9
N2 31 19
N3 19 24
N4 23 21
Unknownb 0 4
Histological lymph nO 1 2 NS
node metastasis nI 22 22
n2 29 17
n3 11 15
n4 8 11
Unknownb 11 13
Penrtoneal PI-) 37 46 NS
dissemination P(+) 45 34
Liver metastasis H(-) 63 64 NS
H(+) 19 16
Lymph node RO 15 11 NS
dissection RI 19 15
R2 38 31
R3 6 8
Unknownb 4 2
Gastrectomy Total 43 42 NS
Partial 39 38
NS, no significant difference; RC, relative curative; RNC, relative
non-curative; ANC, absolute non-curative. Mean standard deviation.
bUnkcnown cases were excluded from the statistical analysis.POSTOPERATIVE CHEMOTHERAPY FOR GASTRIC CANCER
Statistical analsis
Data were analysed using the chi-square test, Mann-Whitney
U-test and Student's t-test. Survival curves were calculated by
the method of Kaplan and Meier. Comparisons were made
by the generalised Wilcoxon test. A P value of less than 0.05
was considered to be significant.
Results
In the 186 patients. entered into this study. 19 (10.2%) had
to be excluded: four had double cancers. eight no surgical
resection. two over 76 years of age at operation and five
macroscopic curative resections. and five (2.7%) dropped out
in the course of treatment; two no ingestion of any drug and
three in group A who were inadequately given 5-FU injec-
tions. The patients were followed in the outpatient depart-
ment at 2 week intervals. Attention was directed to their
general condition. bone marrow function, liver function and
serum carcinoembryonic antigen levels (Maehara et al..
1990a). and at 6 month intervals imagings were taken.
Clinicopathologicalfeatures
Clinicopathological details on the 162 eligible cases (87.10):
82 in group A; 80 in group B. are shown in Table I. There
were no significant differences between the groups with
regard to the distnrbution of prognostic factors. With respect
to surgical procedures: gastric resection and lymph node
dissection. there were no differences between the groups. The
clinicopathological factors related to palliative resection are
shown in Table II. There was no difference between them.
Doses ofdrugs
There was no difference in the dose of each drug between
groups A and B. as shown in Table III.
Survival ratesfor patients in groups A and B
Figure 2 shows the survival curves of 82 patients in group A
and 80 in group B. Generalised Wilcoxon test of the two
survival patterns revealed a P value of 0.169. The 50%
survival was 8.9 months for those in Group A and 12.9
months for those in group B. The 1-year survival rate was
35.5% for group A and 49.0% for group B and the 2-year
survival rate was 19.9% for group A and 28.10% for group B.
Table 11 Comparison of factors involved in noncurative resection
between patients in groups A and B
Group A Group B
Factor (n = 821 (n = 80)
Serosal invasion 78 (95.1°o) 75 (93.8%)
Lymph node metastasis 55 (67.1%) 50 (62.50.)
OW (+) 3 (3.7%6) 6 (7.5°o)
AW(+) 6 (7.3%) 4 (5.0%)
Liver metastasis 19 (23.20,'o) 16 (20.0%o)
Peritoneal dissemination 45 (54.9%'o) 34 (42.5°o)
OW( +): macroscopic cancer infiltration at the oral margin.
AW(+): macroscopic cancer infiltration at the anal margin.
Table III Doses of drugs
Drug Group A Group B
MMC (mg) 61.0 ± 32.4a 54.8 ± 35.0
OK-432 (KE) 44.2 ± 16.9 42.9 10.2'
5-FU (mg) 1186.6 ± 226.5
UFT (g) 63.1 ± 54.9 62.5 51.7
PSK (g) 534.6 ± 424.6 535.9 ± 412.0
MMC: mitomycin C. 5-FU: 5-fluorouracil. UFT: a combined oral
preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil in a
molar ratio of 1:4. OK-432 and PSK: immunomodulators.
'Mean ± standard deviation.
_-
P
n
Time after operation (years)
Fire 2 Survival curves for patients of groups A and B. There
were 82 patients in group A (v) and 80 patients in group B (0).
Tabe IV Toxicities
Toxicit.i Group A Group B
Leukopenia (<3.000cellsmm 24.4 15.0
Anaemia (<3 x 106 cells mm-3) 14.6 15.0
Thrombocytopenia (<1 x 0I cells mm-3) 13.4 11.3
Liver dysfunction: GOT (>100 U) 9.8 11.3
Anorexia 15.9 25.0
Skin pigmentation 1.2 0.0
Nausea. Vomiting 12.2 11.3
Diarrhea 4.9 12.5
'Values = °h of patients fulffiling each criterion for toxicity.
Toxiciti
Table IV summanrses factors related to toxicity. Various side
effects occurred in each group. as did hematologic toxicities.
The rates of anorexia and diarrhea were higher in treatment
group B. but the difference could not be supported statisti-
cally. There was no difference between the treatment groups
with respect to other side effects.
MMC and or fluorinated pyrimidines are prescribed for
patients undergoing resection for gastric cancer. These drugs
can be given alone and in combination with other
antitumour drugs (Kano et al.. 1981; Inokuchi et al., 1984).
A delay in postoperative treatment can lead to negative
results (Higgins et al.. 1983; Engstrom et al., 1985). Fielding
et al. (1983) found no positive effects of adjuvant
chemotherapy with MMC plus 5-FU. but survival time was
lengthened when treatment was begun within 1 month.
Douglass (1985) reported that postoperative chemotherapy
should be initiated at the time of surgical resection. As
tumour cells remaining after noncurative resection may grow
rapidly in the postoperative period (Schabel. 1975; Gunduz et
al.. 1979). the potential to control the remaining tumour foci
is reduced significantly by delaying chemotherapy further in
the postoperative period. The PLCC regimen. which consists
of intermittent administration of MMC and long-term con-
tinuous administration of tegafur and PSK. has lengthened
the survival time of patients with gastric cancer following
noncurative resection (Kano et al.. 1982). We found that the
combination chemotherapy of MMC, tegafur plus PSK im-
proves the 15-year survival of patients with advanced gastnrc
cancer (Maehara et al., 1990c). In an attempt to improve
survival by initiating aggressive chemotherapy early, 5-FU
bolus injections were added to the chemotherapy regimen. As
UFT is more effective than tegafur for patients with stage IV
gastric cancer (Maehara et al.. 1990b), we prescribed UFT
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and PSK for 1 year, for both groups.
5-FU has been prescribed for 5 days, in combination with
other drugs to treat patients with advanced gastric cancer
(Gastrointestinal Tumor Study Group, 1988). The rate of
myelotoxicity of 5-FU is lower in those treated with con-
tinuous infusion, than in those given a bolus injection, in
cases of high dose administration (Seifet et al., 1975; Fraile et
al., 1980). An adequate anastomotic healing has been
ensured. We prescribed a bolus injection of 250 mg of 5-FU
for 5 days. The incidence of side effects did not increase in
the group B, by adding 5-FU infusion to the same regimen
given to group A. This induction chemotherapy with MMC
and 5-FU (MF) was safe for the patients. The 1 year
survival rate was 35.5° in group A, for whom the drug
protocol was similar to that of PLCC (Kano et al., 1982),
and the rate was 49.0% in group B on the aggressive
chemotherapy.
Although there was no definite statistical difference, the
50% survival rate improved 1.4-fold in cases of aggressive
chemotherapy, that is when 5-FU injection was added in the
very early postoperative period. Retrospective analysis
showed that this protocol is effective for patients with gastric
cancer of the differentiated, but not for the undifferentiated
type. A prospective study based on the histopathology is in
progress.
We thank M. Ohara for comments.
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